Leptin decreases the expression of low-density lipoprotein receptor via PCSK9 pathway: Linking dyslipidemia with obesity

Journal of Translational Medicine

Volumn 14, Issue 1, 2016, Pages

  Du, Ying ^a   Li, Sha ^a   Cui, Chuan Jue ^a   Zhang, Yan ^a   Yang, Sheng Hua ^a   Li, Jian Jun ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

LDLR; Leptin; PCSK9

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ATORVASTATIN; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; LEPTIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE P38; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; SERINE PROTEINASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DYSLIPIDEMIA; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; OBESITY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

EID: 84988664194     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-016-1032-4     Document Type: Article

References (36)

1. Sainz N, Barrenetxe J, Moreno-Aliaga MJ, Martinez JA. Leptin resistance and diet-induced obesity: central and peripheral actions of leptin. Metabolism. 2015;64(1):35-46.
2. Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab. 2004;89(6):2595-600.
3. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature. 2006;444(7121):881-7.
4. Fox CS, Massaro JM, Hoffmann U, Pou KM, Maurovich-Horvat P, Liu CY, Vasan RS, Murabito JM, Meigs JB, Cupples LA, et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation. 2007;116(1):39-48.
5. Superko HR, Gadesam RR. Is it LDL particle size or number that correlates with risk for cardiovascular disease? Curr Atheroscler Rep. 2008;10(5):377-85.
6. Rosenson RS. Low high-density lipoprotein cholesterol disorders and cardiovascular risk: contribution of associated low-density lipoprotein subclass abnormalities. Curr Opin Cardiol. 2005;20(4):313-7.
7. Rosenson RS. Colesevelam HCl reduces LDL particle number and increases LDL size in hypercholesterolemia. Atherosclerosis. 2006;185(2):327-30.
8. Chan DC, Watts GF, Redgrave TG, Mori TA, Barrett PH. Apolipoprotein B-100 kinetics in visceral obesity: associations with plasma apolipoprotein C-III concentration. Metabolism. 2002;51(8):1041-6.
9. Attie AD, Seidah NG. Dual regulation of the LDL receptor-some clarity and new questions. Cell Metab. 2005;1(5):290-2.
10. Degawa-Yamauchi M, Bovenkerk JE, Juliar BE, Watson W, Kerr K, Jones R, Zhu Q, Considine RV. Serum resistin (FIZZ3) protein is increased in obese humans. J Clin Endocrinol Metab. 2003;88(11):5452-5.
11. Piestrzeniewicz K, Luczak K, Komorowski J, Maciejewski M, Jankiewicz Wika J, Goch JH. Resistin increases with obesity and atherosclerotic risk factors in patients with myocardial infarction. Metabolism. 2008;57(4):488-93.
12. Melone M, Wilsie L, Palyha O, Strack A, Rashid S. Discovery of a new role of human resistin in hepatocyte low-density lipoprotein receptor suppression mediated in part by proprotein convertase subtilisin/kexin type 9. J Am Coll Cardiol. 2012;59(19):1697-705.
13. Lambert G. Unravelling the functional significance of PCSK9. Curr Opin Lipidol. 2007;18(3):304-9.
14. Jeong HJ, Lee HS, Kim KS, Kim YK, Yoon D, Park SW. Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2. J Lipid Res. 2008;49(2):399-409.
15. Li H, Dong B, Park SW, Lee HS, Chen W, Liu J. Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine. J Biol Chem. 2009;284(42):28885-95.
16. Otero M, Lago R, Lago F, Casanueva FF, Dieguez C, Gomez-Reino JJ, Gualillo O. Leptin, from fat to inflammation: old questions and new insights. FEBS Lett. 2005;579(2):295-301.
17. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994;372(6505):425-32.
18. Arora S. Anubhuti: role of neuropeptides in appetite regulation and obesity-a review. Neuropeptides. 2006;40(6):375-401.
19. Beltowski J. Leptin and atherosclerosis. Atherosclerosis. 2006;189(1):47-60.
20. Guzik TJ, Mangalat D, Korbut R. Adipocytokines-novel link between inflammation and vascular function? J Physiol Pharmacol. 2006;57(4):505-28.
21. Dubey L, Hesong Z. Role of leptin in atherogenesis. Exp Clin Cardiol. 2006;11(4):269-75.
22. Wolk R, Berger P, Lennon RJ, Brilakis ES, Johnson BD, Somers VK. Plasma leptin and prognosis in patients with established coronary atherosclerosis. J Am Coll Cardiol. 2004;44(9):1819-24.
23. El-Zein O, Usta J, El Moussawi L, Kreydiyyeh SI. Leptin inhibits the Na(+)/K(+) ATPase in Caco-2 cells via PKC and p38MAPK. Cell Signal. 2015;27(3):416-23.
24. El-Zein O, Kreydiyyeh SI. Leptin inhibits glucose intestinal absorption via PKC, p38MAPK, PI3 K and MEK/ERK. PLoS ONE. 2013;8(12):e83360.
25. Bao MH, Zhang YW, Zhou HH. Paeonol suppresses oxidized low-density lipoprotein induced endothelial cell apoptosis via activation of LOX-1/p38MAPK/NF-kappaB pathway. J Ethnopharmacol. 2013;146(2):543-51.
26. Park SL, Hwang B, Lee SY, Kim WT, Choi YH, Chang YC, Kim WJ, Moon SK. p21WAF1 Is Required for Interleukin-16-Induced Migration and Invasion of Vascular Smooth Muscle Cells via the p38MAPK/Sp-1/MMP-9 Pathway. PLoS ONE. 2015;10(11):e0142153.
27. Paleczny B, Siennicka A, Zacharski M, Jankowska EA, Ponikowska B, Ponikowski P. Increased body fat is associated with potentiation of blood pressure response to hypoxia in healthy men: relations with insulin and leptin. Clin Auton Res. 2016;26(2):107-16.
28. Sugiyama C, Ishizawa M, Kajita K, Morita H, Uno Y, Matsubara K, Matsumoto M, Ikeda T, Ishizuka T. Platelet aggregation in obese and diabetic subjects: association with leptin level. Platelets. 2007;18(2):128-34.
29. Konstantinides S, Schafer K, Koschnick S, Loskutoff DJ. Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity. J Clin Investig. 2001;108(10):1533-40.
30. Tahergorabi Z, Khazaei M. Leptin and its cardiovascular effects: focus on angiogenesis. Adv Biomed Res. 2015;4:79.
31. Abella V, Scotece M, Conde J, Lopez V, Lazzaro V, Pino J, Gomez-Reino JJ, Gualillo O. Adipokines, metabolic syndrome and rheumatic diseases. J Immunol Res. 2014;2014:343746.
32. Sattar N, Wannamethee G, Sarwar N, Chernova J, Lawlor DA, Kelly A, Wallace AM, Danesh J, Whincup PH. Leptin and coronary heart disease: prospective study and systematic review. J Am Coll Cardiol. 2009;53(2):167-75.
33. Kwakernaak AJ, Lambert G, Dullaart RP. Relationship of proprotein convertase subtilisin-kexin type 9 levels with resistin in lean and obese subjects. Clin Biochem. 2012;45(16-17):1522-4.
34. Agrawal S, Gollapudi S, Su H, Gupta S. Leptin activates human B cells to secrete TNF-alpha, IL-6, and IL-10 via JAK2/STAT3 and p38MAPK/ERK1/2 signaling pathway. J Clin Immunol. 2011;31(3):472-8.
35. Pham DD, Do HT, Bruelle C, Kukkonen JP, Eriksson O, Mogollon I, Korhonen LT, Arumae U, Lindholm D. p75 neurotrophin receptor signaling activates sterol regulatory element-binding protein-2 in hepatocyte cells via p38 mitogen-activated protein kinase and caspase-3. J Biol Chem. 2016;291(20):10747-58.
36. Nepal S, Kim MJ, Hong JT, Kim SH, Sohn DH, Lee SH, Song K, Choi DY, Lee ES, Park PH. Autophagy induction by leptin contributes to suppression of apoptosis in cancer cells and xenograft model: involvement of p53/FoxO3A axis. Oncotarget. 2015;6(9):7166-81.